Potential of capecitabine as first-line therapy for metastatic breast cancer: dosing recommendations in patients with diminished renal function
- PMID: 12123346
- DOI: 10.1093/oxfordjournals.annonc.a000321
Potential of capecitabine as first-line therapy for metastatic breast cancer: dosing recommendations in patients with diminished renal function
Comment on
-
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.Ann Oncol. 2001 Sep;12(9):1247-54. doi: 10.1023/a:1012281104865. Ann Oncol. 2001. PMID: 11697835 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
